Aytu BioPharma, Inc.
Symbole: AYTU
NASDAQ
2.9043
USDPrix du marché aujourd'hui
-0.9631
Ratio P/E
-0.0159
Ratio PEG
16.17M
Cap MRK
- 0.00%
Rendement DIV
Aytu BioPharma, Inc. (AYTU) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 81.66 | 23 | 19.4 | 49.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 122.27 | 28.9 | 21.7 | 28.2 | |||||||||||||||||
balance-sheet.row.inventory | 51.6 | 12 | 10.8 | 16.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 4.13 | 0.9 | 0.6 | 1 | |||||||||||||||||
balance-sheet.row.total-current-assets | 293.27 | 72.8 | 59.9 | 105.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.7 | 3.9 | 6.3 | 8.7 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 65.8 | |||||||||||||||||
balance-sheet.row.intangible-assets | 235.49 | 59 | 70.6 | 85.5 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 235.49 | 59 | 70.6 | 151.3 | |||||||||||||||||
balance-sheet.row.long-term-investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.tax-assets | 1.38 | 1.4 | 0 | 10.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0.8 | 0.8 | 0.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 254.55 | 63.6 | 77.7 | 160.4 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.account-payables | 53.09 | 13.5 | 11 | 19.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 17.7 | 1.6 | 3.9 | 25.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.92 | 14.7 | 14.3 | 2.8 | |||||||||||||||||
Deferred Revenue Non Current | -1.38 | -1.4 | 0 | -11.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.38 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 82.35 | 7.1 | 49.5 | 7.4 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 118.45 | 28.1 | 27.1 | 18.7 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.05 | 0.8 | 2.2 | 3.6 | |||||||||||||||||
balance-sheet.row.total-liab | 402.53 | 97.1 | 91.5 | 128.1 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.retained-earnings | -1230.52 | -304.1 | -288.5 | -178.3 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1375.81 | 343.5 | 334.6 | 315.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 547.82 | - | - | - | |||||||||||||||||
Total Investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.total-debt | 73.62 | 16.4 | 18.2 | 28.3 | |||||||||||||||||
balance-sheet.row.net-debt | -8.04 | -6.6 | -1.2 | -21.3 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -18 | -17.1 | -110.2 | -58.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 8.72 | 8.8 | 10.3 | 9.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 7.31 | 3.3 | 0 | 22.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 3.55 | 6 | 5.2 | 3.6 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 1.71 | -5.8 | -10.9 | 1.7 | |||||||||||||||||
cash-flows.row.account-receivables | -3.79 | -7.2 | 6.5 | 1.5 | |||||||||||||||||
cash-flows.row.inventory | -2.57 | -3.6 | 1.3 | 2.8 | |||||||||||||||||
cash-flows.row.account-payables | 0.19 | 2.4 | -7.7 | -3.2 | |||||||||||||||||
cash-flows.row.other-working-capital | 7.87 | 2.6 | -11 | 0.6 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 2.81 | -0.4 | 76.7 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 6.11 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | -0.4 | -0.1 | -0.1 | 2.4 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.4 | -0.1 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.debt-repayment | -2.39 | -2.3 | -172.5 | -54.9 | |||||||||||||||||
cash-flows.row.common-stock-issued | 3.93 | 15.6 | 11.7 | 45.1 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | -7.22 | -4.4 | 162.3 | 40.2 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -5.68 | 8.9 | 1.5 | 30.3 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0.03 | 3.6 | -30.5 | 1.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 81.66 | 23 | 19.4 | 49.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 81.63 | 19.4 | 49.9 | 48.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 6.11 | -5.1 | -28.8 | -26 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 6.11 | -5.1 | -28.8 | -28.3 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 98.5 | 107.4 | 96.7 | 65.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 36.2 | 40.8 | 44.4 | 36.4 | |||||||||||||||||
income-statement-row.row.gross-profit | 62.29 | 66.6 | 52.3 | 29.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 2.45 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 25.68 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.operating-expenses | 65.31 | 79 | 88.4 | 67.4 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 101.52 | 119.7 | 132.8 | 103.9 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.71 | 4.8 | 4.1 | 23.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -0.31 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -8.26 | -17.1 | 37.2 | -38.2 | |||||||||||||||||
income-statement-row.row.income-before-tax | -17.17 | -17.1 | -110.3 | -58 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 1.25 | -0.1 | -0.1 | 0.3 | |||||||||||||||||
income-statement-row.row.net-income | -16.64 | -17.1 | -110.2 | -58.3 |
Questions fréquemment posées
Quel est le total de Aytu BioPharma, Inc. (AYTU) de l'actif total?
Aytu BioPharma, Inc. (AYTU) Le total des actifs est 136463000.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est 45033000.000.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.632.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est 1.108.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est -0.169.
Quel est le revenu total de l'entreprise?
Le revenu total est -0.084.
Qu'est-ce que Aytu BioPharma, Inc. (AYTU) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est -17051000.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 16361000.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 78961000.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 19529000.000.